Jichishi Pharmaceutical (02616.HK) releases groundbreaking latest preclinical research results on CS2009 (PD-1/VEGF/CTLA-4).

According to the Wise Information Finance APP, on May 6th, Keyston Pharma (02616.HK), an innovative biopharmaceutical company focused on the research and development of anti-tumor drugs, announced at the American Association for Cancer Research (AACR) annual meeting in 2025 that the company had published the pre-clinical research results of its blockbuster product CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibody) in the form of a poster presentation. Currently, the global multicenter Phase I clinical study of CS2009 is ongoing in Australia, with the first patient dosed in March of this year, and future expansion into China and the United States.